Diagnostic review can change the scope before treatment is priced
A German neuroimmunology center may need to review MRI, cerebrospinal-fluid results and laboratory studies before confirming MS or distinguishing it from NMOSD, MOGAD or another disorder. Repeating or extending diagnostics adds a different cost layer from routine follow-up of an established diagnosis.
Disease-modifying therapies have very different resource profiles
Oral, injectable and infusion therapies differ in drug acquisition, pre-treatment testing, infusion-center use and ongoing laboratory or imaging monitoring. A generic 'MS treatment price' therefore hides the most important financial differences between pathways.
Starting, switching and escalating therapy are not the same visit
A stable patient may need a specialist opinion only, while a treatment change can require additional infection screening, vaccination review, pregnancy planning, laboratory testing and a monitoring schedule. Ask the center to state which of these steps are included in its estimate.
Relapse treatment may be a separate acute episode
Clinically significant relapses can require high-dose corticosteroids and, in selected severe cases, further escalation. Acute treatment should be distinguished from the longer-term disease-modifying strategy and may create a separate outpatient or inpatient bill.
Rehabilitation and symptom treatment can sit outside the neuroimmunology invoice
Physiotherapy, occupational therapy, spasticity management, bladder care, fatigue treatment and neurorehabilitation may be delivered by different departments or facilities. International patients should ask which services belong to the quoted hospital episode and which require separate planning.
Official sources
Last source-reviewed 2026-08-31. Cost procedures and published service fees can change, so confirm current terms directly with the provider before transferring money or booking travel.